(Q35031163)

5 August 2017

1 reference

title

Management of acute optic neuritis (English)

1 reference

5 August 2017

1 reference

S J Hickman

1

1 reference

5 August 2017

C M Dalton

series ordinal

2

1 reference

5 August 2017

D H Miller

series ordinal

3

1 reference

5 August 2017

G T Plant

series ordinal

4

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

360

1 reference

5 August 2017

issue

9349

1 reference

5 August 2017

page(s)

1953-1962

1 reference

The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Incidence of optic neuritis in Stockholm, Sweden 1990-1995: I. Age, sex, birth and ethnic-group related patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Optic neuritis: A population-based study in Olrnsted County, Minnesota

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Incidence of optic neuritis in Stockholm, Sweden, 1990-1995: II. Time and space patterns.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Evaluation of the management of optic neuritis: audit on the neurological and ophthalmological practice in the north west of England

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Movement phosphenes in optic neuritis: a new clinical sign

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Uhthoff and his symptom

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Subclinical optic neuropathy in multiple sclerosis. How early VER components reflect axon loss and conduction defects in optic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Pupillary Escape in Disease of the Retina or Optic Nerve

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Relative Afferent Pupillary Defects in Optic Neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Multiple sclerosis associated with uveitis in two large clinic-based series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Long-term visual outcome and complications associated with pars planitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Long-term remyelination after optic neuritis: A 2-year visual evoked potential and psychophysical serial study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Recovery from severe visual loss in optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Visual recovery in patients with optic neuritis and visual loss to no light perception

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Residual symptoms and signs after untreated acute optic neuritis. A one-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Long- and short-term variability of automated perimetry results in patients with optic neuritis and healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Visual resolution in a patient exhibiting a visual fatigue or saturation-like effect: probable multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Pulfrich pendulum phenomenon in patients with a history of acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Optic nerve and chiasmal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Anterior clinoid mucocele masquerading as retrobulbar neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The acute zonal outer retinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Maculopathies that resemble optic neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Chronic relapsing inflammatory optic neuropathy (CRION).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Optic perineuritis: clinical and radiographic features

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Central nervous system sarcoidosis--diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

1 reference

7 January 2021

Atypical features prompting neuroimaging in acute optic neuropathy in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The contribution of magnetic resonance imaging in the differential diagnosis of optic nerve damage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Pattern electroretinography (PERG) and an integrated approach to visual pathway diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Delayed visual evoked response in optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Visual evoked response in diagnosis of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The role of magnetic resonance techniques in understanding and managing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Treatment of acute retrobulbar neuritis with corticotrophin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Treatment of retrobulbar neuritis with corticotrophin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

A trial of corticotrophin gelatin injection in acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Treatmenf of optic neuritis by retrobulbar injection of triamcinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Optic neuritis treatment trial. One-year follow-up results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The optic neuritis treatment trial: three-year follow-up results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

1 reference

7 January 2021

Chickenpox and steroid cards. Amended card is used in Oxford

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

New therapies for optic neuropathies: development in experimental models

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Recovery after optic neuritis in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

A long-term prospective study of optic neuritis: evaluation of risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and early MS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Bilateral optic neuritis. A long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Multisequence MRI in clinically isolated syndromes and the early development of MS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Problems with diagnostic criteria for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Preventing multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

Mistaken treatment of anterior ischemic optic neuropathy with interferon beta-1a

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2911919-2

7 January 2021

10.1016/S0140-6736(02)11919-2

Identifiers

DOI

1 reference

5 August 2017

1 reference